Abstract
We present a case of a patient with low back pain, in which the use of inadequately selected pharmacotherapy resulted in increased pain intensity. The case study showed that the most likely cause of the pain exacerbation was the use of pridinol. Due to the pharmacokinetic and pharmacodynamic profile, pridinol should not be administered as a first line drug to patients with pain, what is additionally associated with the anticholinergic effect of the drug, which impairs the activity of supraspinal antinociceptive cholinergic pathways.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
